v3.26.1
Discontinued Operations (Tables)
 3 Months Ended
Mar. 31, 2026
Restructuring Cost and Reserve [Line Items]  
Schedule of Allocation of Purchase Price

 

Consideration given:    
Consideration given:    
Cash  $210,000 
Holdback   150,000 
Series D Preferred   400,000 
Business Acquisition Cost  $760,000 
      
Assets and liabilities acquired:     
Tradename  $150,000 
Goodwill   610,000 
  $760,000 
Schedule of Constituting Loss from Discontinued Operations

The major classes of line items constituting loss from discontinued operations are as follows:

 

    
   March 31, 2025 
Revenue  $- 
Cost of revenue   - 
Selling, general, and administrative expenses   997,152 
Research and development expenses   265,663 
Impairment loss   14,645,069 
Depreciation and amortization   - 
Interest expense   3,431 
Loss on discontinued operations  $15,911,315 
NAYA Therapeutics [Member]  
Restructuring Cost and Reserve [Line Items]  
Schedule of Allocation of Purchase Price

In the second quarter of 2025, the Company recognized a loss of $1,534,517 upon the disposition of the 80.1% ownership of NTI.

  

     
Consideration received:    
Series C-1 Preferred  $2,466,810 
NTI Note Receivable   4,803,175 
NTI Series A Preferred   3,879,611 
Business acquisition cost  $11,149,596 
      
Assets and liabilities divested:     
Cash  $6,569 
Other current assets   16,700 
Tradename   257,000 
In process R&D   14,571,000 
Goodwill   3,011,638 
AP & accrued liabilities   (4,804,016)
Debt   (374,778)
Net assets  $12,684,113 
      
Loss on disposition  $1,534,517